Routine molecular biomarkers for diagnosis, predicting prognosis and stratifying patients for therapies now include assessing B-Raf proto-oncogene (BRAF) and isocitrate dehydrogenase 1/2 (IDH1/2) mutations, O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation as well as predictor of response to temozolomide, a pivotal drug in GBM therapy [2,4,5,6,7]. This evidence concerns the gene MGMT and glioblastoma.